Skip to content
TrialScanner

NCT02477618

A Study With SAGE-547 for Super-Refractory Status Epilepticus

Phase 3CompletedSUPNLead

Registry record

Lead sponsor
Supernus Pharmaceuticals, Inc.
Conditions
Super-Refractory Status Epilepticus
Primary completion
Jul 18, 2017Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02477618 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02477618: A Study With SAGE-547 for... | TrialScanner